Quality of Life and Long-Term Mortality in Patients with Advanced Chronic Heart Failure Treated with Intermittent Low-Dose Intravenous Inotropes in an Outpatient Setting
Authors:
Open Access
- 17 September 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 4 (2) , 122-129
Abstract
There are limited data on the effect of low-dose, intermittent inotropic therapy in an outpatient setting on the quality of life (QOL) in patients with advanced refractory heart failure (HF) symptoms. We aimed to analyse the effect of this treatment modality on QOL and subsequent survival. The study population comprised 287 consecutive patients with advanced refractory HF symptoms who were treated with low-dose, intravenous intermittent inotropic therapy in the HF Day Care Service at Sheba Medical Centre between September 2000 and September 2012. All patients completed a baseline Minnesota Living with Heart Failure Questionnaire (MLWHFQ), and 137 (48%) completed a 1 year follow-up questionnaire. MLWHFQ scores' means ranged from 0 (better QOL) to 5 (worse QOL). Mean age was 68 ± 12, 86% were men, 77% had ischaemic cardiomyopathy, and the mean left ventricle ejection fraction (LVEF) was 26% ± 13. The mean baseline MLWHFQ score was 3.1 (±1), while the mean at 1 year of treatment was of 2.7 (±1.1), indicating an overall improvement in QOL associated with intermittent low-dose inotrope therapy (p < 0.01). Multivariate analysis showed that younger age, non-ischaemic cardiomyopathy, and worse renal function were independently associated with improvement in QOL at 1 year. Improvement in QOL was not associated with a significant survival benefit during subsequent follow-up. In patients with advanced refractory HF symptoms, treatment with low-dose, intermittent intravenous inotropes in an outpatient setting is associated with significant improvement in QOL. However, improvement in QOL in this population does not appear to affect subsequent long-term survival.Keywords
This publication has 33 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsEuropean Heart Journal, 2009
- Clinical epidemiology of heart failureHeart, 2007
- Need for hospice and palliative care services in patients with end‐stage heart failure treated with intermittent infusion of inotropesClinical Cardiology, 2004
- Outcomes in heart failure patients with preserved ejection fractionJACC, 2003
- Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart FailureNew England Journal of Medicine, 2001
- Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudyThe American Journal of Cardiology, 1993
- Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendanAmerican Heart Journal, 1992
- Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluationThe American Journal of Cardiology, 1987
- Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failureAmerican Heart Journal, 1986